Clinical trial
Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA
NCT00351403 is registered in ClinicalTrials.gov with FGK Clinical Research GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA
- Lead sponsor
- FGK Clinical Research GmbH
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- January 31, 2010
- Enrollment
- 390 (estimated)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.